Health Canada has issued a market authorization with conditions for Voxzogo (vosoritide for injection) for the treatment of achondroplasia – Biomarin International

Health Canada has issued a Notice of Compliance with conditions (NOC/c) for Voxzogo (vosoritide for injection) a modified recombinant human C-type natriuretic peptide 39 (CNP-39) for the treatment of achondroplasia.

Approved indication: To increase linear growth in patients with achondroplasia who are 4 months of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

Authorization status: approved with conditions, pending the results of confirmatory clinical trials to verify clinical benefit. Patients should be advised of the conditional nature of the authorization.